CURRICULUM VITAE

Name: Richard E. Gregg, M.D.
Email: richard.gregg1@gmail.com
Telephone: 609-439-8203
Address: 7 Linden Lane
Pennington, NJ 08534

Education:

Feb. 1970 - B.S. Biochemistry, Iowa State University
Aug. 1971 - M.S. Biochemistry, Iowa State University
June 1976 - M.D. Stanford University

Board Certification:

Internal Medicine, 1979
Endocrinology and Metabolism, 1981

Brief Chronology of Employment:

1976 - 1977	Intern, Internal Medicine, Strong Memorial Hospital, Rochester, NY
1977 - 1978	Resident, Internal Medicine, Strong Memorial Hospital, Rochester, NY
1978 - 1982	Clinical Associate, Molecular Disease Branch, NHLBI, NIH, Bethesda, MD
1982 - 1984	Medical Staff Fellow, Molecular Disease Branch, NHLBI, NIH, Bethesda, MD
1984 - 1988	Senior Investigator, Molecular Disease Branch, NHLBI, NIH, Bethesda, MD
1988 - 1996	Executive Director, Department of Metabolic Diseases, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ
1996-1998	Vice President, Metabolic Diseases, Drug Discovery Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ
1999-2001	Vice President, Metabolic and Cardiovascular Drug Discovery Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ
2001-2007	Vice President, Clinical Discovery Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ

Military Service:

Commissioned Corps, United States Public Health Service, 1978 – 1988

Societies:

American Association for the Advancement of Science
American College of Physicians
American Heart Association, Council on Atherosclerosis
American Diabetes Association

Honors:

Undergraduate

Phi Kappa Phi (Scientific Honorary Society), Iowa State University, 1970
Award for the Most Outstanding Student in One's Major Field (Biochemistry), Iowa State University, 1970
Graduated with Honors and Distinction, Iowa State University, 1970

Medical School

It was the policy of Stanford University School of Medicine during the time of my enrollment not to give scholastic honors or awards.

Western Student Medical Research Forum Award for Meritorious Research, 1975 and 1976

Professional

Fellow of the Council on Atherosclerosis, American Heart Association, 1982
Fellow of the American College of Physicians, 1985
Pfizer Traveling Lectureship, Montreal Clinical Research Institute, 1985
Visiting Professor, Shandong Medical College, Jinan, China, 1986

Member of Board of Directors

American Federation for Aging Research (1999-2005)
Robert Wood Johnson University Hospital at Hamilton (2001-present)

Research Experience:

1969 - 1971	Mechanism of protein biosynthesis in eukaryotic organisms
1974 - 1976	Metabolism of triglycerides in experimentally induced acute and chronic uremia
1978 - 1988	Metabolism of lipoproteins and apolipoproteins in human subjects
1988 - 2001	Led Drug Discovery activities for BMS in Cardiovascular and Metabolic Diseases; regulation of lipoprotein metabolism; regulation of carbohydrate and fatty acid metabolism; regulation of weight; aging and chronic degenerative diseases; atherosclerosis and vessel wall biology; thrombosis. Twenty-five compounds nominated for clinical development; seven compounds still in clinical development.
2001-2007	Led all Exploratory Development and Clinical Pharmacology activities for BMS; Phase I&II, mechanism of action, and proof of concept studies; Clinical Pharmacology studies in all phases; development and use of novel biomarkers; pharmacogenetic and genomic studies; developed modeling and simulation capabilities.

BMS Special Activities:

1995 - 1998	Led the Exploratory Development working groups for squalene synthase inhibitors and for MTP inhibitors
1996	Drug Discovery Productivity Initiative Member of Task Force Responsible for writing Drug Discovery Handbook Change leader; responsible for planning and rolling out Productivity Initiative to all of Drug Discovery
1997	Selected to participate in the inaugural CEO's Forum (two day meeting with CEO for high potential mid-level executives)
1998	Led the team that developed the vision for Applied Genomics and initiated the efforts for BMS in genetics/genomics/biotechnology
2001	Core member of Drug Discovery Redesign Task Force Member of Clinical Development Redesign Task Force Developed vision, organizational structure, and processes for Clinical Discovery Led the team to develop structure and processes for Exploratory Development Teams (strategic planning and development coordination for Exploratory Development compounds) Responsible for selection and assimilation of members of DuPont Pharma's Drug Metabolism and Clinical Pharmacology Departments into BMS Clinical Discovery
2002	Led the team to develop the structure and processes for Exploratory Clinical Research Teams (exploratory development clinical operations) Led the team to coordinate closure of the Wilmington Drug Discovery site and assimilate employees into other BMS sites and projects Led the Drug Discovery Strategic Portfolio and Staffing team (set strategies and processes for BMS Drug Discovery)
2002 - 2007	Co-leader of Exploratory Development Operating Committee

Member Brand Development Operating Committee (governance body for Full Development)
Member Institute Executive Committee
Member Medical Review Committee (most senior medical review group for BMS)
Responsible for approving First in Human studies

BIBLIOGRAPHY

1. Gregg, R.E. and Heintz, R.L.: The inhibition of eukaryotic aminoacyl tranferase I by chartreusin. Arch. Biochem. and Biophys. 152:451-456, 1972.

2. Gregg, R.E., Mondon, C.E., Reaven, E.P., and Reaven, G.M.: Effect of acute uremia on triglyceride kinetics in the rat. Metabolism 25:1557-1566, 1976.

3. Gregg, R.E., Diamond, A., and Reaven, G.M.: Effect of chronic uremia and glucocorticoid therapy on triglyceride kinetics in rat. Metabolism 26:875-882, 1977.

4. Gregg, R.E., Zech, L.A., Schaefer, E.J., and Brewer, H.B., Jr.,: Type III hyperlipoproteinemia: Defective metabolism of an abnormal apolipoprotein E. Science 211:584-586, 1981.

5. Ghiselli, G., Schaefer, E.J., Zech, L.A., Gregg, R.E., Brewer, H.B. Jr.: Increased prevalence of apolipoprotein E4 in type V hyperlipoproteinemia. J. Clin. Invest. 70:474-477, 1982.

6. Ghiselli, G., Gregg, R.E., Zech, L.A , Schaefer, E.J, Brewer, H.B., Jr.: Phenotype study of apolipoprotein E isoforms in hyperlipoproteinemia patients. The Lancet ii:405-407, 1982.

7. Schaefer, E.J, Zech, L.A., Gregg, R.E., Brewer, H.B., Jr.: Metabolism of high density lipoproteins. In: Proceedings of the USA-USSR First Lipoprotein Symposium. U.S. Department of Health and Human Services, NIH Publication No. 83-1966, Washington, D.C., U.S. Government Printing Office, pp. 105-122, 1982.

8. Goldstein, D.S., Dionne, R., Sweet, J., Gracely, R., Brewer, H.B., Jr., Gregg, R.E., and Keiser, H.R.: Circulatory, plasma catecholamine, cortisol, lipid and psychological responses to a real-life stress (Third molar extractions): Effects of diazepam sedation and of inclusions of epinepherine with the local anesthetic. Psychosomatic Medicine 44:259-272, 1982.

9. Brown, R.E., Gregg, R.E., and Hood, J.C.: Droperidol treatment of streptozocen-induced nausea and vomiting. Drug Intell. and Clin. Pharm. 16:775-776, 1982.

10. Cogan, D.G., Chu, F.C., Barringer, J. and Gregg, R.E.: Maculo Halo Syndrome. Tr. Am. Ophth. Soc. 80:184-192, 1983.

11. Gregg, R.E., Zech, L.A., and Brewer, H.B., Jr.: Apolipoprotein E alleles in severe hypertriglyceridemia. The Lancet 1:353, 1983.

12. Gregg, R.E.: Molecular and metabolic defects. In: Type III hyperlipoproteinemia: Diagnosis, molecular defects, pathology, and treatment. Brewer, H.B., Jr., Moderator

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.